ArticleVeterinary world2025
Development and validation of a recombinant capsid protein-based indirect enzyme-linked immunosorbent assay for serological detection of duck circovirus in commercial flocks.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overview of waterfowl circovirus: research progress and future perspectives.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Duck circovirus (DuCV) is an immunosuppressive pathogen linked to poor growth, feather abnormalities, and increased susceptibility to co-infections, leading to significant economic losses in duck production. Rapid and large-scale serological screening tools are essential for epidemiological surveillance and biosecurity. This study aimed to develop and validate an indirect enzyme-linked immunosorbent assay (iELISA) based on a recombinant capsid (Cap) protein for sensitive and specific detection of antibodies against DuCV. Materials and Methods: The Results: The optimized iELISA used 12 μg/well of antigen and a 1:20 serum dilution, producing the highest positive-to-negative optical density ratio. Receiver operating characteristic curve analysis yielded an area under the curve of 0.996, with 97.5% sensitivity and 98.1% specificity. No cross-reactivity was detected with sera positive for duck Tembusu virus, duck viral enteritis virus, or Conclusion: The developed recombinant Cap-based iELISA provides a reliable, specific, and reproducible tool for large-scale DuCV serosurveillance. Its high diagnostic accuracy and scalability support its application in flock-level monitoring, pre-movement screening, and epidemiological studies, facilitating improved biosecurity and informed disease control strategies within the duck industry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.